- Home
- RLTY vs ABEO Comparison
RLTY vs ABEO Comparison
Compare RLTY & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- ABEO
- Stock Information
- Founded
- RLTY 2022
- ABEO 1974
- Country
- RLTY United States
- ABEO United States
- Employees
- RLTY N/A
- ABEO N/A
- Industry
- RLTY Investment Managers
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- RLTY Finance
- ABEO Health Care
- Exchange
- RLTY Nasdaq
- ABEO Nasdaq
- Market Cap
- RLTY 253.7M
- ABEO 281.0M
- IPO Year
- RLTY N/A
- ABEO 1980
- Fundamental
- Price
- RLTY $15.00
- ABEO $4.15
- Analyst Decision
- RLTY
- ABEO Strong Buy
- Analyst Count
- RLTY 0
- ABEO 5
- Target Price
- RLTY N/A
- ABEO $18.20
- AVG Volume (30 Days)
- RLTY 86.7K
- ABEO 1.6M
- Earning Date
- RLTY 01-01-0001
- ABEO 11-13-2025
- Dividend Yield
- RLTY 9.35%
- ABEO N/A
- EPS Growth
- RLTY N/A
- ABEO N/A
- EPS
- RLTY N/A
- ABEO 0.99
- Revenue
- RLTY N/A
- ABEO $400,000.00
- Revenue This Year
- RLTY N/A
- ABEO N/A
- Revenue Next Year
- RLTY N/A
- ABEO $324.71
- P/E Ratio
- RLTY N/A
- ABEO $4.24
- Revenue Growth
- RLTY N/A
- ABEO N/A
- 52 Week Low
- RLTY $11.38
- ABEO $3.93
- 52 Week High
- RLTY $14.60
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- RLTY 45.43
- ABEO 21.95
- Support Level
- RLTY $14.85
- ABEO $5.29
- Resistance Level
- RLTY $15.09
- ABEO $5.41
- Average True Range (ATR)
- RLTY 0.19
- ABEO 0.25
- MACD
- RLTY -0.01
- ABEO -0.10
- Stochastic Oscillator
- RLTY 39.64
- ABEO 2.33
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.